Last reviewed · How we verify
NCT06242522: FERTILAVE
Fertility and Pregnancy After Avelumab Treatment
NA trial testing Telephone interview in Gestational Trophoblastic Tumours in 50 participants. Status unknown.
1 April 2025
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 1 April 2024 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Telephone interview
Conditions studied
- Gestational Trophoblastic Tumours — all drugs for Gestational Trophoblastic Tumours →
- Immune Checkpoint Inhibitors — all drugs for Immune Checkpoint Inhibitors →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, female only, with Gestational Trophoblastic Tumours or Immune Checkpoint Inhibitors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, initially evaluated in advanced non-curative pathologies, are now being evaluated in adjuvant or even neoadjuvant curative treatment conditions. This paradigm shift is leading to the treatment of young women, particularly in the context of gestational trophoblastic tumours. Given the potential autoimmune side-effects affecting endocrine functions, as well as their impact on maternal-foetal tolerance mechanisms, accurate assessment of post-ICT fertility is necessary. In the coming years, treatment with anti-PD-L1 (avelumab) could become a cornerstone of the therapeutic strategy for patients with gestational trophoblastic tumours. However, these patients are often young and of childbearing age, so safety of use in terms of fertility and successful pregnancies is an essential factor in the widespread use of immunotherapy as a treatment option. Some studies have reported the possibility of conceiving after avelumab treatment, but no cohort has been reported. This study aims to explore fertility and the course of potential pregnancy in 50 patients treated with anti-PD-L1 (avelumab) over the last 5 years in several French centres.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The basic biology of NK cells and its application in tumor immunotherapy.
Jiang P, Jing S, Sheng G, Jia F. · · 2024 · cited 17× · PMID 39221244 · DOI 10.3389/fimmu.2024.1420205 -
The potential role of exercise in mitigating fertility toxicity associated with immune checkpoint inhibitors (ICIs) in cancer patients.
Jamrasi P, Tazi M, Zulkifli NA, Bae JH, et al · · 2024 · cited 1× · PMID 39616333 · DOI 10.1186/s12576-024-00950-3
Verify or expand the search:
- PubMed search for NCT06242522
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Telephone interview
Trials testing the same drug.
- NCT06313294 — Postoperative Follow-up Via Text Messages Automated Versus Telephone in Patients With Continuous Regional Anesthesia · NA · completed
- NCT04430335 — Telephone-Based Intervention to Treat Depression and Anxiety in Hispanic Cancer Survivors · NA · completed
- NCT04343430 — Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation · NA · recruiting
- NCT04343443 — Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation · NA · recruiting
- NCT04282486 — Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease · completed
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06242522 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06242522.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing